Conference abstract · 24 Oct 2018
Conference abstractPublished 23 Sep 2013
Accelerating biosimilars mAbs to market: A predefined process coupled with consultative services
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biosimilars manufacturers face unique challenges, in a fast growing segment of the biotech industry. Process parameters for biosimilars are defined early in molecule development, with limited scope for later revisions. Process development and characterization occur simultaneously. Speed in development must include rapid optimization of all parameters. Therefore, it is vital to design manufacturability into the process at this early stage. We propose a template designed for biosimilars mAbs manufacturers to accelerate speed to clinic and minimize risk of failure. A process is defined for rapid production of mAbs at 100 g scale, with the majority of the process control parameters predetermined and fixed. Parameters such as chromatography column flow rates, buffer selection, column height, membrane and column loading, auxiliary filtration and buffer management are all preconfigured both in terms of process inputs and single use engineered systems. This enables clarified cell culture through purification and formulated bulk drug substance with minimal process development. The benefits include little to no process development time, minimal risk in scale up and tech transfer, and reduced capital investment. Data for two mAbs illustrates this plug and play approach. This process design, with large scale proven products coupled with consultative services, enables an accelerated approach to the biosimilars mAbs market.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 26 Oct 2015
The Characterisation of Biosimilar mAbs using Biologically Relevant and Sensitive ADCC methodologies
Conference abstract · 26 Oct 2015
Production of Biosimilar MAbs in Transgenic Animals– Opportunities and Challenges
Short communication · 29 Aug 2023
Impact of a clinical pharmacist in a multidisciplinary consultation on the switch to a biosimilar for inflammatory rheumatic diseases
Review article · 27 Feb 2017
A Review of the Concept, Relevance, Processes, and Planning Strategies for Marketing Library and Information Services
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Jennifer Campbell”

